Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
What to know about Labor Day and its history
Recommended
The sun now sets before 8 p.m. Will we ever do away with the time change?
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
44.15
+1.61 (+3.78%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gsk Plc ADR
< Previous
1
2
3
4
Next >
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
August 06, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 01, 2024
From
GSK plc
Via
Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
July 11, 2024
From
GSK plc
Via
Business Wire
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
June 07, 2024
From
GSK plc
Via
Business Wire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer
June 03, 2024
From
GSK plc
Via
Business Wire
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
June 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
June 02, 2024
From
GSK plc
Via
Business Wire
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
April 03, 2024
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Via
MarketBeat
Exposures
Product Safety
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
March 16, 2024
From
GSK plc
Via
Business Wire
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 07, 2024
From
GSK plc
Via
Business Wire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
February 08, 2024
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally
From
Alector, Inc.
Via
GlobeNewswire
23andMe Reports Third Quarter Fiscal 2024 Financial Results
February 07, 2024
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473
From
23andMe, Inc.
Via
GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
February 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
February 06, 2024
From
GSK plc
Via
Business Wire
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
January 24, 2024
From
Elegen
Via
Business Wire
GSK Enters Agreement to Acquire Aiolos Bio
January 09, 2024
From
Aiolos Bio, Inc.
Via
Business Wire
GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning
January 08, 2024
Via
Investor Brand Network
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
December 12, 2023
From
GSK plc
Via
Business Wire
3 cheap 'stock'-ing stuffers Wall Street is bullish on
December 07, 2023
These three companies have Wall Street feeling bullish and are trading under $10, making them ideal ‘stock'-ing stuffers for hard to shop for traders.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
Via
MarketBeat
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
November 13, 2023
From
GSK plc
Via
Business Wire
GSK is a remedy for the winter investment blahs
November 07, 2023
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...
From
23andMe, Inc.
Via
GlobeNewswire
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
October 27, 2023
From
Alector, Inc.
Via
GlobeNewswire
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
October 25, 2023
From
GSK plc
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.